|
A4: Establish VO2 standards for successful completion of mission tasks.
|
|
A6: Develop pre-flight, in-flight, and post-flight evaluations to determine if VO2 standards are met.
|
|
A7: Develop the most efficient and effective exercise program for the maintenance of VO2 standards.
|
|
A9: Identify and validate exploration countermeasure hardware for the maintenance of VO2 standards.
|
|
Acute - 5: What are the optimal SPE alert and dosimetry technologies? (Closed. Technology maturation transferred to Advanced Exploration Systems)
|
|
Acute - 6: What are the most effective shielding approaches to mitigate acute radiation risks, how do we know, and implement? (Closed. Transferred to Operations)
|
|
AEH 1: What are the unique properties of lunar dust that affect physiology? (Closed)
|
|
AEH 2: What is the toxicity of lunar dust in the respiratory system? (Closed)
|
|
AEH 4: What is the dermal and ocular toxicity of lunar dust? (Closed)
|
|
AEH 5: What are the permissible exposure limits for inhalation of lunar dust? (Closed)
|
|
AEH Watch Item/NSBRI Research: What are the effects of lunar gravity on permissible exposure limits for inhalation of lunar dust? (Closed)
|
|
B16: Can inhibitors of stone formation be sufficiently provided through dietary sources?
|
|
B5: What is the current state of knowledge regarding renal stone formation due to spaceflight?
|
|
B6: What are the contributing factors other than loss of bone mineral density?
|
|
B7: Is it necessary to increase crew fluid intake and, if possible, to what extent will it mitigate stone formation?
|
|
B8: Do pharmaceuticals work effectively in spaceflight to prevent renal stones?
|
|
B9: What is the frequency of post-flight stone formation; the incidence and types of stones; and the time course of stone formation? How does stone formation correlate with food intake and hydration status?
|
|
BMed-101: We need to identify, quantify, and validate the key selection factors for astronaut cognitive and behavioral strengths (e.g., resiliency) and operationally-relevant performance threats for increasingly Earth independent, long-duration, autonomous, and/or long-distance exploration missions.
|
|
BMed-102: Given exposures to spaceflight hazards (space radiation, isolation), how do we identify individual susceptibility, monitor molecular/biomarkers and acceptable thresholds, and validate behavioral health and CNS/neurological/neuropsychological performance measures and domains of relevance to exploration class missions?
|
|
BMed-103: What are the validated, efficacious treatments (individual or Team-based) and/or countermeasures to prevent adverse behavioral conditions, CNS/neurological, and/or psychiatric disorders caused by either single and/or integrated exposures to spaceflight hazards during exploration class missions?
|
|
BMed-104: Given the potentially negative spaceflight associated CNS changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated modifications to habitat/vehicle to mitigate stressors impacting on CNS / cognition / behavioral health?
|
|
BMed-105: Given the potentially negative spaceflight associated CNS/cognitive changes and behavioral experiences of stressors during long-duration missions (e.g., isolation, confinement, reduced sensory stimulation, altered gravity, space radiation), what are validated medical or dietary countermeasures to mitigate stressors impacting on CNS / cognition / behavioral health?
|
|
BMed-106: Given increasing Earth independent long-duration missions with resulting communications delays, how do we maintain personal relations / interactions (family, friends and colleagues) and mitigate effects on astronauts’ behavioral health and performance during exploration class missions?
|
|
BMed-107: What are the long-term changes and risks to astronaut health post-mission that, when using a continuity of care model, helps retrospectively identify and understand individual susceptibility (e.g., hereditary, dose, thresholds) to mitigate adverse CNS, cognitive, and behavioral health changes resulting from long-duration exploration missions, promoting the behavioral health of current and future crews?
|
|
BMed-108: Given each crewmember will experience multiple spaceflight hazards simultaneously, we need to identify and characterize the potential additive, antagonistic, or synergistic impacts of multiple stressors (e.g., space radiation, altered gravity, isolation, altered immune, altered sleep) on crew health and/or CNS/ cognitive functioning to develop threshold limits and validate countermeasures for any identified adverse crew health and/or operationally-relevant performance outcomes.
|